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OBJECTIVE—The study objective was to assess the relationship between b-cell function and
HbA1c.
RESEARCH DESIGN AND METHODS—A total of 522 Mexican American subjects
participated in this study. Each subject received a 75-g oral glucose tolerance test (OGTT)
aftera10-to12-hovernightfast.InsulinsensitivitywasassessedwiththeMatsudaindex.Insulin
secretoryratewasquantitatedfromdeconvolutionoftheplasmaC-peptideconcentration.b-Cell
functionwasassessedwiththeinsulinsecretion/insulinresistance(IS/IR)(disposition)indexand
was related to the level of HbA1c.
RESULTS—At HbA1c levels ,5.5%, both the Matsuda index of insulin sensitivity and IS/IR
index were constant. However, as the HbA1c increased .5.5%, there was a precipitous decrease
in both the Matsuda index and the IS/IR index. Subjects with HbA1c =6 . 0 –6.4% had a 44 and
74% decrease in the Matsuda index and the IS/IR index, respectively, compared with subjects
with HbA1c ,5.5% (P , 0.01 for both indices). Subjects with normal glucose tolerance and
HbA1c ,5.7% had b-cell function comparable to that of subjects with normal glucose tolerance
with HbA1c =5 . 7 –6.4%. However, subjects with impaired fasting glucose or impaired glucose
tolerance had a marked decrease in b-cell function independent of their HbA1c level.
CONCLUSIONS—The results of the current study demonstrate that in Mexican Americans, as
HbA1cincreases.6.0%,bothinsulinsensitivityandb-cellfunctiondecreasemarkedly.Performing
an OGTT is pivotal for accurate identiﬁcation of subjects with impaired b-cell function.
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I
n 1997, the American Diabetes Asso-
ciation(ADA)reviseditscriteriaforthe
diagnosis of type 2 diabetes and de-
termined that subjects with fasting plasma
glucose(FPG).126mg/dLand2-hplasma
glucose $200 mg/dL are considered to
have type 2 diabetes (1). These cut points
were chosen on the basis of the increased
incidence of diabetic retinopathy rather
than on the presence of metabolic abnor-
malities (i.e., insulin resistance and b-cell
dysfunction) that are responsible for type
2 diabetes (1).
Impaired b-cell function is the prin-
cipal factor responsible for the develop-
ment and progression of type 2 diabetes
(2). In addition to b-cell dysfunction,
subjects with type 2 diabetes manifest se-
vere insulin resistance in skeletal muscle,
liver, and adipocytes (3–6). Insulin resis-
tanceistheearliestmetabolicabnormality
detected in subjects destined to develop
type 2 diabetes. In response to insulin re-
sistance, the b-cell appropriately increases
insulin secretion and normal glucose toler-
ance (NGT) ismaintained.However, when
b-cellfailureensues,glucoseintolerancede-
velops. Initially, this is manifest as impaired
glucose tolerance (IGT) and subsequently
as overt diabetes (1). Thus, impaired b-cell
function is an essential condition in the de-
velopment of type 2 diabetes (1).
Although normal b-cell function is
pivotal to the maintenance of NGT,
b-cell failure develops long before hyper-
glycemiabecomesevident.Recentstudies
have demonstrated that the decrease
inb-cellfunctionbeginsintherangecon-
sidered to be well within NGT according
to the 1997 ADA criteria (7–10). Studies
that have related b-cell function to FPG
(7,8) and 2-h plasma glucose (9,10) con-
centrations reported that b-cell function
progressively declined with the increase
in both FPG and 2-h plasma glucose
from the low normal range to the high
normal range, to the impaired glucose tol-
erant and diabetic ranges. These results in-
dicate that the decrease in b-cell function,
which is the primary factor responsible for
the deterioration of glucose tolerance, is a
continuumwithnothresholdabovewhich
b-cell dysfunction develops.
ADA recently changed the diagnostic
criteria for type 2 diabetes to include
individuals with HbA1c $6.5%; high-
risk individuals are deﬁned as having an
HbA1c =5 . 7 –6.4% (11,12). No data are
available relating the HbA1c to b-cell
function. Therefore, the aim of the cur-
rent study was to examine the relation-
ship between b-cell function and HbA1c.
RESEARCH DESIGN AND
METHODS
Subjects
The participants in this study included
522 subjects of Mexican American de-
scent who were part of the San Antonio
Veterans Administration Genetic Epidemi-
ology Study (5). In the Veterans Admin-
istration Genetic Epidemiology Study,
Mexican American families with one dia-
betic and one nondiabetic parent and two
siblings with type 2 diabetes were re-
cruited through advertising within the
medical center and in local newspapers.
Subjects responding to the advertisement
were screened with a 75-g oral glucose
tolerance test (OGTT). All family mem-
bers who responded to the advertisement
and fulﬁlled the inclusion criteria agreed
to participate in the study. This study re-
ports on 522 subjects who were free of
diabetes and received a 75-g OGTT and
had NGT, IGT, impaired fasting glucose
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Pathophysiology/Complications
ORIGINAL ARTICLE(IFG), or type 2 diabetes based on the
2003 glucose criteria established by ADA
(13). None of the subjects with type 2 di-
abetes knew that he/she had diabetes, and
type 2 diabetes was diagnosed for the ﬁrst
time with the OGTT. Thus, no type 2 di-
abetic subject in the study had used anti-
diabetic medications.
All subjects had normal liver, cardio-
pulmonary, and kidney function as
determined by medical history, physical
examination, screening blood tests, elec-
trocardiogram, and urinalysis. No subject
with NGT, IFG, IGT, or type 2 diabetes
was taking any medication known to af-
fect glucose tolerance. Body weight was
stable(62kg)foratleast3monthsbefore
the study in all subjects. No subject par-
ticipated in an excessively heavy exercise
program. The study protocol was ap-
proved by the institutional review board
of the University of Texas Health Science
Center, San Antonio, and informed writ-
tenconsentwasobtainedfromallsubjects
beforetheirparticipation.Allstudieswere
performed at the General Clinical Re-
search Center of the University of Texas
Health Science Center at 0800 h after a
10- to 12-h overnight fast.
OGTT
Before the start of the OGTT, a small
polyethylene catheter was placed into an
antecubital vein, and blood samples were
collected at 230, 215, 0, 15, 30, 45, 60,
75,90,105,and120minforthemeasure-
ment of plasma glucose, C-peptide, and
insulin concentrations. On the day of the
OGTT, height, weight, and waist circum-
ference were determined at the narrowest
part of the torso, and a blood sample was
obtained for HbA1c measurement.
Analytic techniques
Plasma glucose concentration was mea-
sured by the glucose oxidase reaction
(Glucose Oxidase Analyzer, Beckman,
Fullerton, CA). Plasma insulin and C-
peptideconcentrationsweremeasuredby
radioimmunoassay (Linco Research, St.
Louis, MO). HbA1c was measured with
high-performance liquid chromatogra-
phy.
Calculations
Insulin secretory rate (ISR) during the
OGTT was calculated from deconvolu-
tion of the plasma C-peptide concentra-
tion as previously described (8), and the
incremental area under the ISR curve was
related to the incremental area under the
plasma glucose curve (DISR[AUC]0–120/
DG[AUC]0–120). The insulin secretion/
insulin resistance (IS/IR) (disposition)
index was determined by dividing DISR/
DG by the severity of insulin resistance
[DISR(AUC)0–120/DG(AUC)0–120 4 IR],
asmeasuredbytheinverseoftheMatsuda
index (14). The Matsuda index incorpo-
rates both hepatic and muscle compo-
nents of insulin resistance, correlates
wellwith themeasurementofinsulinsen-
sitivity from the euglycemic insulin
clamp, and was calculated as follows:
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The incremental area under the ISR
curve[DISR(AUC)0–120]andtheincremental
areaundertheplasmaglucoseconcentra-
tion curve [DG(AUC)0–120] were calcu-
lated according to the trapezoid rule.
Statistical analysis
Subjects were divided into deciles based
on the HbA1c,a n dt h em e a nH b A 1c in
each decile was related to the mean IS/IR
index in the same decile. Data are pre-
sentedasthemean6SD.Forcomparison
between two groups, Student t test was
used. To compare the mean of more
than two groups, ANOVA was used. Sig-
niﬁcantdifferenceswereconﬁrmedbythe
Bonferroni test. Statistical signiﬁcance
was considered at P , 0.05.
RESULTS—Table 1 presents the char-
acteristics of the study participants. The
21.5% of subjects had NGT, 35.9% had
IFG and/or IGT, and 42.6% had type 2
diabetes according to the 2003 ADA cri-
teria (13). However, if subjects were clas-
siﬁed on the basis of the HbA1c level
accordingtotheADAclinicalpracticerec-
ommendation (12), only 29.5% had type
2d i a b e t e s( H b A 1c $6.5%) and 21.4%
were characterized as high-risk individu-
als (HbA1c =5 . 7 –6.4%), whereas 49.1%
had NGT (HbA1c ,5.7%) (Table 2).
We divided subjects with HbA1c
,5.7% (columns A and B in Table 3)
and high-risk individuals with HbA1c =
5.7–6.4% (columns D and E in Table 3)
into two groups based on plasma glu-
cose values during the OGTT: i)N G T
(FPG ,100 mg/dL and 2-h plasma glu-
cose ,140 mg/dL, columns A and D) and
ii) IFGand/orIGT (FPG= 100–125mg/dL
or 2 h plasma glucose = 140–199 mg/dL,
columns BandE),and comparedthe met-
abolic characteristics of the various
groups. Table 3 demonstrates that, in
subjects with NGT with HbA1c =5 . 7 –
6.4% (column D), the Matsuda index
of insulin sensitivity was decreased by
35% compared with NGT subjects with
HbA1c ,5.7% (column A) (3.1 6 0.5 and
4.5 60.4, respectively,P= 0.03). However,
the IS/IR (disposition) index was compara-
ble between the two groups (Table 3). Like-
wise, in subjects with IFG and/or IGT and
an HbA1c =5 . 7 –6.4% (column E), the
Matsudaindexofinsulinsensitivitywassig-
niﬁcantly reduced compared with subjects
with HbA1c ,5.7% (column B) (3.1 6 0.5
and 2.2 6 0.2, respectively, P , 0.001).
However, the IS/IR index in subjects with
IFG and/or IGT was similarly reduced in
both groups (Table 3). Changing the
HbA1c cut points to ,5.5%, 5.5–6%, 6.0–
6.49%, and 6.5–7.0% (Table 3) demon-
strated that NGT groups with HbA1c
,5.5% (column G) and HbA1c =5 . 5 –
6.0% (column H) were more insulin-
sensitive and had a greater insulin secre-
tion/insulin resistance (disposition) index
Table 1—Characteristics of study
participants: diagnosis of glucose tolerance
status is based on the 2003 ADA criteria
Age (years) 47 6 1
Sex (M/F) 178/344
BMI (kg/m
2) 33.0 6 0.3
Waist circumference (cm) 100.9 6 0.8
FPG (mg/dL) 120 6 2
HbA1c (%) 6.2 + 0.07
NGT (%) 21.5
IFG and/or IGT (%) 35.9
Type 2 diabetes (%) 42.6
Table 2—Relationship between HbA1c and diagnostic category (NGT, IFG and/or IGT, and
type 2 diabetes) based on glucose criteria during the OGTT according to the 2003 ADA criteria
NGT IFG and/or IGT Type 2 diabetes Total
HbA1c ,5.7% 97 128 31 256
HbA1c =5 . 7 –6.4% 15 56 40 111
HbA1c $6.5% 0 3 151 154
HbA1c ,5.5% 90 103 28 221
HbA1c =5 . 5 –6.0% 18 62 21 101
HbA1c .6.0% 5 22 172 199
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Kanat and Associatescompared with subjects with IFG and/or
IGT with HbA1c ,5.5% (column H) and
HbA1c =5 . 5 –6% (column K). However,
subjects with HbA1c =6 –6.5% (column
M) and 6.5–7% (column N) had a marked
decrease in the insulin secretion/insulin re-
sistance index (0.1 6 0.01 and 0.07 6
0.02, respectively) compared with sub-
jects with HbA1c ,6.0%.
Whenallsubjectswerepooledintoone
group and the Matsuda index of insulin
sensitivity and IS/IR index were related to
the HbA1c as a continuous variable, the re-
lationship between the two was highly
nonlinear. Whole-body insulin sensitivity,
measured with the Matsuda index, re-
mained unchanged up to an HbA1c =5 . 5 % .
However, as the HbA1c increased .5.5%,
there was a steep decrease in the Matsuda
index (Fig. 1). Subjects with HbA1c =6 . 0 –
6.4% had a 44% decrease in insulin sen-
sitivity compared with subjects with
HbA1c ,5.5% (P , 0.01).
The postload plasma glucose concen-
tration, measured as the incremental area
under the plasma glucose curve (ΔG0–120),
remained unchanged with the increase in
HbA1c up to a value = 5.5%, and, as ob-
served when the HbA1c exceeded 5.5%,
ΔG0–120 progressively increased with
t h ei n c r e a s ei nH b A 1c. Likewise, insulin
secretion, measured as the incremental
area under the ISR (ΔISR0–120/ΔG0–120)
curve, remained unchanged up to an
HbA1c = 5.5%, and, as observed when
the HbA1c increased .5.5%, ΔISR0–120/
ΔG0–120 progressively decreased with
further increases in the HbA1c. b-Cell
function,measuredwiththeIS/IR(dispo-
sition)index,didnotchangesigniﬁcantly
up to an HbA1c = 5.7%. However, as the
HbA1c increased .5.7%, there was a
marked decrease in b-cell function. Sub-
jects with HbA1c =6 . 0 %h a da6 2 %d e -
crease in the IS/IR index compared with
subjects with HbA1c ,5.7%.
CONCLUSIONS—AlthoughtheHbA1c
represents the mean plasma glucose level
(fasting and postprandial) throughout the
day, the results of the current study demon-
strate that, in Mexican Americans, the rela-
tionship between b-cell function and HbA1c
differs signiﬁcantly from the relationship
between b-cell function and the fasting
and 2-h plasma glucose concentrations
(7–10). Similarly, the relationship be-
tween insulin sensitivity and HbA1c dif-
fers from that obtained using the fasting
and 2-h plasma glucose concentrations
(3). Although both insulin sensitivity
(measured with the euglycemic insulin
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b-Cell function and HbA1cclamp)(3)andb-cellfunction(measured
with the IS/IR index) progressively de-
creased with the increase in both fasting
(8) and 2-h (9) plasma glucose concen-
trations, they remained unchanged with
the increase in HbA1c up to a value =
5.5%; thereafter, both insulin sensitivity
and b-cell function precipitously de-
creased with increasing HbA1c levels
.5.5%.
ADA and the International Diabetes
Federation recently revised their criteria
for the diagnosis of type 2 diabetes and
high-risk individuals (11,12). With both
criteria, subjects with an HbA1c .6.5%
are diagnosed with type 2 diabetes. The
ADA criteria state that subjects with
HbA1c =5 . 7 –6.5% are at high risk to
develop diabetes, whereas the interna-
tional expert committee suggested that
subjects with HbA1c =6 . 0 –6.5% repre-
sent high-risk individuals. The results
of the current study demonstrate that, in
MexicanAmericans,subjectswith HbA1c=
6.0%alreadymanifestsevereformsofboth
coredefects that are characteristicoftype2
diabetes, i.e., insulin resistance (44%
decrease in insulin sensitivity) and b-cell
dysfunction(62% decreaseinIS/IR index).
InsubjectswithHbA1c=6.0–6.4%,insulin
sensitivity, measured with the Matsuda in-
dex, did not differ from that in subjects
with HbA1c $6.5%, and the IS/IR index
wasdecreasedby74%comparedwithsub-
jects with HbA1c ,5.5%. Furthermore,
the majority of studies that have evaluated
the relationship between the incidence
of diabetic retinopathy and HbA1c have
reported a signiﬁcant increase in the inci-
denceofdiabeticretinopathyastheHbA1c
increased .6.0% (15–20). For example,
thethresholdfortheincreaseinretinopathy
was 5.5% in the 2005–2006 National
Health and Nutrition Examination Survey
(15) and the Hisayama study (16), 6.0%
in the National Health and Nutrition Ex-
amination Survey III (17), 6.2% in the
Pima Indian study (18), and 6.3% in the
Egyptian study (19). Moreover, when
the risk for heart attack and stroke was
related to HbA1c in nondiabetic subjects
in the Atherosclerosis Risk in Communi-
ties Study (21), subjects with HbA1c =
6–6.4% had a 78% increase in the risk
for heart attack and stroke compared
with subjects with HbA1c ,5.5%. Taken
together, these results indicate that sub-
jects with HbA1c =6 . 0 –6.4% manifest
maximal insulin resistance with ;75%
decrease in b-cell function and increased
risk ofdiabeticretinopathyand cardiovas-
cular disease. On the basis of these patho-
physiologic and anatomic abnormalities,
these subjects should be considered to
have type 2 diabetes, and an HbA1c cut
point of 6.0% seems more appropriate
for the diagnosis of type 2 diabetes than
the HbA1c cut point of $6.5% established
by both ADA and the international expert
committee. Moreover, consistent with
other studies (22–25), an HbA1c cut point
of 6.5% underdiagnoses many subjects
with type 2 diabetes. The prevalence of
type 2 diabetes in this cohort was only
29.5% (HbA1c $6.5%) compared with
42.6% with the 2003 ADA criteria based
on fasting and 2-h plasma glucose levels
(Table 2). Conversely, if an HbA1c cut
point of 6.0% is used to diagnose type 2
diabetes, the prevalence of type 2 diabe-
t e si nt h i sc o h o r tw o u l db e3 8 % ,w h i c hi s
comparable to that with the ADA glucose
criteria.Thus,anHbA1ccutpointof6.5%
forthediagnosisoftype2diabeteswould
leave ;30% of subjects with type 2 dia-
betesundiagnosed.Moreover,insubjects
with HbA1c =6 . 0 –6.5%, only ;5% were
nondiabetic and ;95% had type 2 dia-
betes based on the results of the OGTT
(Table2).Thus,decreasingtheHbA1ccut
pointfortype2diabetesfrom6.5to6.0%
would result in only a small number of
false positives.
Although both insulin sensitivity and
b-cell function remained unchanged in
individuals with HbA1c ,5.7%, approxi-
mately half of the subjects in this group
had IFG and/or IGT and therefore are at
increased risk of future type 2 diabetes
and could beneﬁt from an intervention
program aimed to reduce their future
type 2 diabetes risk, e.g., weight loss
and exercise. However, according to the
new ADA criteria (HbA1c ,5.7%), this
large group of individuals would be con-
sidered to have NGT and would remain
unidentiﬁed as having glucose intoler-
ance. Conversely, when subjects were
stratiﬁed on the basis of the results of the
OGTT,those withIFG andorIGT (despite
having HbA1c ,5.7%) had a marked de-
crease in b-cell function compared with
subjects with NGT (55% decrease in IS/
IR index, Table 3). Likewise, subjects
with NGT with HbA1c =5 . 7 –6.4% had
comparable b-cell function compared
with subjects with NGT with HbA1c
,5.7%. Subjects with IFG and/or IGT
with HbA1c = 5.7–6.4% had a further de-
crease in b-cell function. These results
demonstrate that the OGTT provides a
better tool to identify subjects with b-cell
failure compared with the HbA1c.I ti s
likely that challenging the b-cell with a
glucose load provides a “stress test” to
theb-cellandexposesmoresubtledecrea-
ses in b-cell function compared with
measurements taken during the fasting
state, e.g., HbA1c. Because b-cell function
is the principal factor responsible for
the development of type 2 diabetes, these
results underscore the importance of
Figure 1—Relationship between HbA1c and DISR0–120/DG0–120 (A), DG(AUC)0–120 (B),
Matsuda index of insulin sensitivity (C), and IS/IR index (D)i na l l5 2 1s u b j e c t s .
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Kanat and Associatesperforming an OGTT for the assessment
of b-cell health and identiﬁcation of sub-
jects at increased future risk for type 2
diabetes.
A limitation to this study is that both
insulin sensitivity and b-cell function
were measured with OGTT-derived indi-
ces. Although these indices were vali-
dated with the insulin clamp, additional
studies with the gold standard measure-
ments (euglycemic insulin clamp and
hyperglycemic clamp) are desirable to
provide deﬁnitive evidence. Because of
increased rate of obesity in Mexican
Americans (mean BMI = 33), b-cell dys-
function could become evident at an ear-
lierstageofglucoseintolerancecompared
with other ethnic groups. Therefore, val-
idation of the present ﬁndings in other
ethnic groups is warranted.
Insummary,theresultsofthecurrent
study demonstrate that Mexican Ameri-
can subjects with HbA1c .6% manifest
both core defects of type 2 diabetes in
severe form (44 and 74% decrease in in-
sulin sensitivity and b-cell function, re-
spectively). In addition, a cut point of
HbA1c =6 . 0 %i sc o m p a r a b l et ot h e
OGTT in identifying subjects with type
2 diabetes. These observations, together
with the increase in diabetic microvas-
cular complications in subjects with
HbA1c .6.0%, favor using a cut point
of HbA1c = 6.0% for the diagnosis of
type 2 diabetes. Furthermore, the results
of this study demonstrate that the OGTT
represents a better tool for the identiﬁca-
tion of subjects with b-cell dysfunction
who are at increased future risk for type
2d i a b e t e s .
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